Compare CRTO & PSNL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRTO | PSNL |
|---|---|---|
| Founded | 2005 | 2011 |
| Country | France | United States |
| Employees | 3649 | N/A |
| Industry | Advertising | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 780.6M | 729.1M |
| IPO Year | 2013 | 2019 |
| Metric | CRTO | PSNL |
|---|---|---|
| Price | $16.41 | $5.99 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 10 | 5 |
| Target Price | ★ $34.00 | $12.20 |
| AVG Volume (30 Days) | 235.3K | ★ 1.9M |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 38.95 | 33.58 |
| EPS | ★ 0.15 | N/A |
| Revenue | ★ $2,296,692,000.00 | $69,648,000.00 |
| Revenue This Year | N/A | $15.34 |
| Revenue Next Year | $5.54 | $41.46 |
| P/E Ratio | $5.92 | ★ N/A |
| Revenue Growth | ★ 27.65 | N/A |
| 52 Week Low | $15.58 | $3.84 |
| 52 Week High | $28.91 | $11.50 |
| Indicator | CRTO | PSNL |
|---|---|---|
| Relative Strength Index (RSI) | 37.25 | 46.27 |
| Support Level | N/A | $5.81 |
| Resistance Level | $20.10 | $6.99 |
| Average True Range (ATR) | 0.90 | 0.46 |
| MACD | -0.31 | 0.06 |
| Stochastic Oscillator | 18.63 | 60.38 |
Criteo SA is an ad-tech company in the digital advertising market. Its technology allows retailer advertisers to launch multichannel and cross-device marketing campaigns in real time. With real-time return on investment analysis of the ads, the firm's clients can adjust their marketing strategies dynamically. It has two reportable segments: Retail Media and Performance Media. Retail Media: This segment encompasses revenue generated from brands, agencies, and retailers for the purchase and sale of retail media digital advertising inventory and audiences, and services. Performance Media: This segment encompasses targeting capabilities and supply and AdTech services. The majority of its revenues is generated from the performance media segment.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.